Kiechi and co-authors reported that blockade of RANKL improved hepatic insulin resistance and prevented DM development in an in vivo study.[10] However, the effect of denosumab upon glycemic and metabolic parameters in humans is not clear. This evidence concerns the gene TNFSF11 and diabetes mellitus.